EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (the "Agreement") is entered into as of June 29, 2000 ("Effective Date") by and among ABBOTT LABORATORIES, an Illinois corporation, having a principal place...Exclusive License and Development Agreement • October 16th, 2002 • Rubicon Medical Corp • Surgical & medical instruments & apparatus • Illinois
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT by and between and Ascletis BioScience Co. Ltd. Dated January 18, 2019Exclusive License and Development Agreement • June 23rd, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is executed as of January 18, 2019 by and between 3-V Biosciences, Inc., a corporation organized under the laws of Delaware (“3-V”), having a principal place of business at 3715 Haven Ave. Suite 220, Menlo Park, CA 94025, and Ascletis BioScience Co. Ltd. (also known as 歌礼生物科技（杭州）有限公司), a corporation under the laws of China having a registered office at Room 1102，Building D，198 Qidi Road, HIPARK, Xiaoshan District, Hangzhou, China (“Ascletis”). 3-V and Ascletis are sometimes collectively referred to herein as the “Parties” or individually as a “Party”.
Exclusive License and Development Agreement between Sorrento Therapeutics, Inc. and China Oncology Focus LimitedExclusive License and Development Agreement • November 25th, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made and entered into as of this 3rd day of October, 2014 (“Effective Date”) between Sorrento Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America (“USA”) with its principal offices at 6042 Cornerstone Court West, Suite B, San Diego, California 92121 US (“SORRENTO”), and China Oncology Focus Limited, a company organized and existing under the laws of British Virgin Islands with its registered office at Offshore Incorporations Centre, P.O. BOX 957, Road Town, Tortola, British Virgin Islands (“Lee’s”), an Affiliate of Lee’s Pharmaceutical Holdings Limited with a principal offices at Unit 110-111, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Shatin, Hong Kong.
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • March 26th, 2008 • SafeStitch Medical, Inc. • Blank checks • Illinois
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”) is made as of the 26th day of May 2006, by and between Creighton University (the “University”) and SafeStitch LLC, a Virginia limited liability company (the “Company”). References to an Article, Section, or paragraph mean an Article, Section or paragraph of this Agreement, unless otherwise specified.
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • October 29th, 2013 • Cempra, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) to the EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT, dated as of May 8, 2013, by and between CEMPRA PHARMACEUTICALS, INC (“Cempra”) and TOYAMA CHEMICAL CO., LTD. (“Toyama”) is hereby effective as of September 26, 2013. Capitalized terms not defined herein shall have the meaning given to them in the Original Agreement.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • October 16th, 2002 • Rubicon Medical Corp • Surgical & medical instruments & apparatus
